1. Introduction {#sec1}
===============

Current pathogenic models of Alzheimer\'s disease (AD) propose that the pathophysiological process begins with amyloid-β plaque accumulation, represented as a sigmoid curve with a slow, age-related accumulation followed by a rapid, disease-related accumulation and finally ending in saturation [@bib1], [@bib2], [@bib3], [@bib4], [@bib5]. Approximately 20%--40% of adults aged over 60 years demonstrate elevated levels of amyloid, despite being cognitively normal [@bib1], suggesting that while amyloid might be necessary for disease pathogenesis, it is not sufficient to explain the clinical symptoms and course of AD. After the initial amyloid deposition, or even concurrent with amyloid deposition, there is regionally specific deposition of neurofibrillary tangles made up of hyperphosphorylated tau protein [@bib1]. Further downstream, structural magnetic resonance imaging (MRI) has shown that cortical atrophy mirrors the distribution of tau pathology and is a ubiquitous feature of clinical AD [@bib6], [@bib7]. Cortical thinning as measured on structural MRI is a biomarker for neuronal death and is the most proximal biomarker to cognitive decline [@bib1].

Clinical diagnosis of AD during an individual\'s lifetime may differ from pathological diagnosis of AD at postmortem analysis, and a meta-analysis showed there is relatively poor agreement between clinical and pathological diagnoses of AD, with sensitivity and specificity ranging between 71%--87% and 44%--71%, respectively [@bib8], [@bib9]. The inclusion of AD biomarkers has been suggested as a method for increasing the accuracy of clinical diagnoses [@bib10], [@bib11]. However, even at a given AD biomarker profile, there is still a large amount of within-individual variability in clinical AD development and progression, which may be attributable to genetic and lifestyle factors, as well as the presence of other critical morbidities [@bib12]. Mixed brain pathologies account for dementia in most older individuals, with 75% of individuals with a pathological AD diagnosis also showing one or more vascular pathologies [@bib12]. Cerebrovascular disease (CVD) is of particular interest because it occurs in approximately 16%--46% of elderly and up to 51% in the oldest old [@bib12].

White matter hyperintensities (WMHs) are areas of increased signal visualized on T2-weighted MRI sequences that result from macrostructural changes that lead to decreased lipid content and increased water content. The most widely accepted biological model of WMH etiology is that damage to blood vessels leads to chronic hypoperfusion [@bib13], while other biological explanations, such as Wallerian degeneration, suggest that primary damage from pathology, such as neurofibrillary tangles, leads to axonal death [@bib14], [@bib15]. WMHs are widely used as an imaging-based biomarker of small vessel CVD [@bib16], [@bib17], [@bib18]. There is a large pathological overlap between small vessel CVD and AD, and WMH burden has been linked to cortical atrophy, cognitive decline, and clinical AD diagnosis [@bib18], [@bib19]. Importantly, there is strong age dependence for both amyloid and WMH burden, and there are common vascular risk factors for AD and CVD [@bib19]. Understanding the interplay between amyloid deposition and CVD, and how they each contribute to neurodegeneration, may provide insight into potentially shared pathways of disease. In the present study, we investigated the longitudinal relationship between biomarkers of amyloid, CVD, and neurodegeneration, and the extent to which early events, such as amyloid or CVD, drive neurodegeneration over time in a large, longitudinal cohort.

2. Methods {#sec2}
==========

Data used in the preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0020}). The ADNI was launched in 2003 as a public-private partnership, led by a principal investigator, Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. For up-to-date information, see [www.adni-info.org](http://www.adni-info.org){#intref0025}.

Six hundred four subjects (n = 224 normal controls \[NCs\], 291 MCI, 93 AD) from the ADNI study underwent longitudinal AV45 positron emission tomography imaging, as well as T1, T2, and proton density MRI scans to quantify fibrillar amyloid deposition, WMH, and cortical thickness, respectively. Subjects had up to 12 time points (up to 10 years) of imaging data (N for each visit after visit 1: 216, 215, 189, 168, 157, 135, 112, 63, 27, 15, 3, 1 NC; 267, 261, 253, 240, 215, 175, 127, 73, 38, 18, 7, 1 MCI; 82, 76, 69, 59, 50, 17 AD). Global WMH volume was estimated at University of California-Davis using spatial and contextual priors for WMH as the sum of cortical lobes (frontal, occipital, parietal, temporal) [@bib20], [@bib21], [@bib22]. Global AV45 standard uptake value ratio (SUVR) was estimated at University of California-Berkeley as the ratio of cortical regions implicated in Thal staging of amyloid plaques (frontal, anterior/posterior cingulate, lateral parietal, lateral temporal) to a composite white matter reference region (whole cerebellum, brainstem/pons, subcortical white matter) [@bib23], [@bib24]. Global cortical thickness was estimated at University of California-San Francisco using FreeSurfer 5.1 (<http://surfer.nmr.mgh.harvard.edu/>) with longitudinal processing [@bib25] as the mean of AD-associated regions (medial/inferior temporal, temporal pole, angular gyrus, superior/inferior frontal, superior parietal, supramarginal gyrus, precuneus) [@bib26], [@bib27].

Analyses of covariance and chi-squared tests compared continuous and categorical demographic information, respectively, across clinical diagnostic group. Similarly, mean AV45 SUVR, WMH volume, and cortical thickness, and rates of change in each, were compared across clinical diagnostic group. Imaging biomarkers were used in two ways: first as categorical variables and second as fully continuous variables. Similar to the method of amyloid positivity determination at University of California-Berkeley [@bib28], thresholds for abnormal amyloid levels were determined as the upper 95% confidence interval of the mean in normal controls. Using all available data from ADNI (i.e., not restricted to the 608 subjects with all three imaging biomarkers), abnormal biomarker threshold was determined for amyloid (n = 833 NC scans, 0.82 SUVR) and log-transformed WMH (n = 1774 NC scans, 0.80 mm^3^). Chi-squared tests were used to compare the prevalence of biomarker abnormality by diagnosis.

Next, a series of pairwise linear mixed-effects models with unbalanced designs and repeated measures was used to investigate associations between AV45 SUVR, WMH volume, and cortical thickness, including a random subject factor (e.g., AV45 SUVR on cortical thickness, AV45 SUVR on WMH volume, and WMH volume on cortical thickness). Since linear mixed-effects models handle unbalanced designs (e.g., unequal number of subjects or visits with each imaging biomarker) by using all available data, models have different degrees of freedom. Full models including all three biomarkers simultaneously were used to investigate additive or synergistic contributions of amyloid and CVD on neurodegeneration (e.g., AV45 SUVR and WMH volume on cortical thickness). Pairwise and full growth curve models were also run to investigate the associations between AV45 and/or WMH volume on cortical thinning rate (e.g., AV45 SUVR\*time on cortical thickness, WMH volume\*time on cortical thickness).

All models were tested with covariate adjustment by clinical diagnostic group, and statistical significance was evaluated at *P* \< .05 (IBM SPSS Statistics for Windows, Version 23.0, IBM Corp., Armonk, NY). Covariates of interest included subject-mean centered age, apolipoprotein epsilon 4 (APOE-ɛ4), sex, education, and baseline intracranial total volume (ICV). Linear mixed-effects models are presented in tables as follows: Biomarker ∼ Clinical Diagnoses + Age + Sex + APOE4 + Education + ICV + Intercept. Growth curve models are as follows: Biomarker ∼ Time + Clinical Diagnoses + Age + Sex + APOE4 + Education + ICV + Time\*Clinical Diagnoses + Time\*Age + Time\*Sex + Time\*APOE4 + Time\*Education + Time\*ICV + Intercept, but are presented only as Time interaction parameters in subsequent tables.

3. Results {#sec3}
==========

Diagnostic groups differed in the frequency of APOE-ɛ4 (APOE4+: NC: 26% \< MCI: 46% \< AD: 74%; χ(3) = 63.6, *P* \< .001), sex distribution (male: NC: 46% \< MCI: 59% NC \< AD: 56%; χ(3) = 8.6, *P* = .04), number of years of education (NC: 17 ± 3 years \> MCI: 16 ± 3, NC \> AD: 16 ± 3; F(2,603) = 3.8, *P* = .02), and ICV (NC: 1508 ± 156 cm^3^ \<MCI: 1550 ± 157, AD: 1505 ± 161 \<MCI; F(2,553) = 5.9, *P* = .003), but not by baseline age (NC: 74 ± 6 years, MCI: 73 ± 7 years, AD: 73 ± 8; F(2,603) = 1.6, *P* = .21). As expected, AV45 SUVR increased (NC \< MCI \< AD), WMH volume increased (NC \< AD), and cortical thickness decreased (NC \> MCI \> AD) across diagnostic groups ([Table 1](#tbl1){ref-type="table"}). AV45 SUVR rate decreased across diagnostic groups (NC \> MCI, NC \> AD), indicating a possible plateau in amyloid deposition during MCI or AD ([Table 1](#tbl1){ref-type="table"}), proposed in the sigmoid trajectories of biomarker progression [@bib1], [@bib2]. Rate of change in WMH volume and cortical thinning rate were not significantly different between clinical diagnostic groups ([Table 1](#tbl1){ref-type="table"}). While not significant, rate of change in WMH volume increased across clinical diagnostic groups as expected, but cortical thinning rate in AD was slower than that in the normal control or MCI group ([Table 1](#tbl1){ref-type="table"}).Table 1AV45 standard uptake value ratio (SUVR), white matter hyperintensity (WMH) volume, and cortical thickness and rates of change in each by clinical diagnosisOutcomeWMH volumeWMH volume rateAmyloid SUVRAmyloid SUVR rateCortical thicknessCortical thinning rateInterceptB = 0.08 \[−8.9, 9.1\] *P* = .95B = −2.8 \[−8.7, 3.10\] *P* = .38**B = 1.00 \[0.83, 1.16\] *P* \< .001**B = −0.011 \[−0.045, 0.022\] *P* = .26**B = 2.44 \[2.27, 2.62\] *P* \< .001**B = −0.088 \[−0.197, 0.021\] *P* = .15Clinical diagnosisB~AD~ = 1.10 \[0.09, 2.12\]\
B~MCI~ = 0.83 \[−0.01, 1.67\] *P* = .098B~AD~ = 0.32 \[−0.37, 1.01\]\
B~MCI~ = 0.51 \[−0.10, 1.12\] *P* = .16**B~AD~ = 0.053 \[0.032, 0.074\]**\
**B~MCI~ = 0.027 \[0.012, 0.042\] *P* \< .001**B~AD~ = −0.006 \[−0.013, 0.0004\]\
B~MCI~ = −0.001 \[−0.006, 0.005\] *P* = .11**B~AD~ = −0.099 \[−0.121, −0.077\]**\
**B~MCI~ = −0.025 \[−0.042, −0.007\] *P* \< .001**B~AD~ = 0.009 \[−0.004, 0.022\]\
B~MCI~ = 0.006 \[−0.005, 0.017\] *P* = .79Age**B = 0.52 \[0.39, 0.66\] *P* \< .001B = 0.075 \[0.006, 0.143\] *P* = .034B = 0.004 \[0.002, 0.007\] *P* = .001**B = −1.6E-5 \[−0.0009, 0.0009\] *P* = .97**B = −0.015 \[−0.018, −0.013\] *P* \< .001B = −0.001 \[−0.002, −2.4E-5\] *P* = .045**SexB~M~ = −0.13 \[−1.88, 1.62\] *P* = .88B~M~ = −0.14 \[−1.31, 1.03\] *P* = .81B~M~ = −0.02 \[−0.056, 0.007\] *P* = .12B~M~ = −0.0002 \[−0.006, 0.006\] *P* = .96B~M~ = −0.031 \[−0.065, 0.003\] *P* = .074B~M~ = −0.0005 \[−0.024, 0.023\] *P* = .97APOE4B~E4~ = 1.07 \[−0.37, 2.52\] *P* = .15B~E4~ = 0.09 \[−0.89, 1.08\] *P* = .85**B~E4~ = 0.144 \[0.120, 0.169\] *P* \< .001B~E4~ = 0.008 \[0.003, 0.014\] *P* = .002B~E4~ = −0.034 \[−0.063, −0.006\] *P* = .018**B~E4~ = −0.014 \[−0.035, 0.006\] *P* = .17EducationB = −0.06 \[−0.32, 0.20\] *P* = .66B = −0.02 \[−0.20, 0.15\] *P* = .80**B = −0.005 \[−0.010, −0.0004\] *P* = .035**B = −6.5E-5 \[−0.001, 0.0009\] *P* = .89B = 0.003 \[−0.002, 0.008\] *P* = .31B = 0.001 \[−0.003, 0.005\] *P* = .64Intracranial total volumeB = 4.0E-6 \[−1.1E-6, 9.1E-6\] *P* = .13B = 1.6E-6 \[−1.7E-6, 4.9E-6\] *P* = .33B = 1.3E-8 \[−8.3E-8, 1.1E-7\] *P* = .79B = 6.7E-9 \[−1.1E-8, 2.5E-8\] *P* = .46B = 2.3E-8 \[−7.6E-8, 1.2E-7\] *P* = .65B = 2.1E-8 \[−3.7E-8, 7.9E-8\] *P* = .47[^2]

Following the amyloid cascade hypothesis, downstream neurodegeneration in key AD regions would not be likely to occur without sufficient amyloid burden. To investigate the apparent slowing in cortical thinning rate in AD, individuals were categorized by biomarker abnormality rather than clinical diagnosis ([Fig. 1](#fig1){ref-type="fig"}). The proportion of individuals with abnormally high amyloid increased across diagnostic groups, in the expected direction (NC: 30.1% \< MCI: 53.4% \< AD: 84.2%; χ(2) = 139.6, *P* \< .001). Similarly, abnormally high WMH volume prevalence increased across diagnostic groups as expected (NC: 55.5% \< MCI: 60.9% \< AD: 80.3%; χ(2) = 71.1, *P* \< .001). Note that there was an incomplete prevalence (e.g., \<100%) of abnormally high amyloid in the clinically diagnosed AD group and that the subjects with the highest WMH volume were in the NC group ([Fig. 1](#fig1){ref-type="fig"}). Cortical thickness was significantly lower in individuals with abnormally high amyloid compared to normally low amyloid ([Table 2](#tbl2){ref-type="table"}). Cortical thinning rate was only significantly different from zero in individuals with abnormally high WMH volume, but not significantly different between the four biomarker abnormality classifications ([Table 2](#tbl2){ref-type="table"}).Fig. 1Distribution of AV45 standard uptake value ratio (SUVR) and log-transformed white matter hyperintensity (WMH) volume by clinical diagnostic group. Dotted line represents abnormality threshold (upper 95% confidence interval in normal control group from larger sample \[right\]) for each biomarker. ∗ Represents outliers in SPSS graphs. Abbreviations: AD, Alzheimer\'s disease; MCI, mild cognitive impairment.Table 2Cortical thickness and cortical thinning rate by biomarker abnormality classificationsCortical thicknessCortical thinning rateBiomarker abnormality profileB~LOW\ Amyloid,\ LOW\ WMH~ = 2.73 \[2.58, 2.88\]\
B~LOW\ Amyloid,\ HIGH\ WMH~ = 2.61 \[2.58, 2.64\]\
**B~HIGH\ Amyloid,\ LOW\ WMH~ = 2.47 \[2.38, 2.57\]\***\
**B~HIGH\ Amyloid,\ HIGH\ WMH~ = 2.51 \[2.49, 2.54\]\***B~LOW\ Amyloid,\ LOW\ WMH~ = −0.002 \[−0.016, 0.013\]\
**B~LOW\ Amyloid,\ HIGH\ WMH~ = −0.008 \[−0.012, −0.003\]\*\***\
B~HIGH\ Amyloid,\ LOW\ WMH~ = −0.002 \[−0.011, 0.008\]\
**B~HIGH\ Amyloid,\ HIGH\ WMH~ = −0.008 \[−0.012, −0.005\]\*\***Age**B = −0.028 \[−0.036, −0.019\] *P* \< .001**B = 8.1E-5 \[−0.003, 0.003\] *P* = .96SexB~M~ = −0.016 \[−0.065, 0.034\] *P* = .53B~M~ = 0.007 \[−0.014, 0.029\] *P* = .50APOE4B~E4+~ = −0.009 \[−0.054, 0.037\] *P* = .70B~E4+~ = −0.011 \[−0.032, 0.009\] *P* = .27EducationB = 0.008 \[−0.0003, 0.015\] *P* = .059**B = 0.004 \[0.0003, 0.007\] *P* = .03**Intracranial total volumeB = 8.1E-8 \[−7.8E-8, 2.4E-7\] *P* = .32B = 1.3E-8 \[-5.5E-8, 8.1E−8\] *P* = .71[^3][^4]

To further investigate the associations among amyloid, WMH, and neurodegeneration, imaging biomarkers were used as fully continuous variables in independent, pairwise linear mixed-effects models ([Fig. 2](#fig2){ref-type="fig"}). AV45 SUVR was not associated with WMH volume ([Supplementary Table 1](#appsec1){ref-type="sec"}). AV45 SUVR was negatively associated with cortical thickness and was significantly different between clinical diagnostic groups such that the association was more negative in MCI and AD compared with NC ([Supplementary Table 2](#appsec1){ref-type="sec"}). Similarly, WMH volume was negatively associated with cortical thickness and was significantly different between clinical diagnostic groups such that the association was more negative in MCI and AD compared with NC ([Supplementary Table 2](#appsec1){ref-type="sec"}). In a full linear mixed-effects model (i.e., including all three imaging biomarkers), the same associations survive as in the pairwise models ([Table 3](#tbl3){ref-type="table"}).Fig. 2(A) Pairwise spaghetti plots between longitudinal measures of cortical thickness, AV45 standard uptake value ratio (SUVR), and log-transformed white matter hyperintensity (WMH) volume. Each line represents a subject. (B) Spaghetti plots between longitudinal measures of cortical thickness, AV45 SUVR, and log-transformed WMH volume against time.Table 3Full linear mixed-effects models and growth curve models between AV45 standard uptake value ratio (SUVR), white matter hyperintensity (WMH) volume, and cortical thickness by clinical diagnosisCortical thicknessCortical thinning rateInterceptB = 2.73 \[2.41, 3.05\] *P* \< .001B = 2.72 \[2.36, 3.07\] *P* \< .001B = −0.053 \[−0.198, 0.092\] *P* = .39B = −0.048 \[−0.209, 0.113\] *P* = .21Clinical diagnosisB~AD~ = 0.38 \[0.08, 0.68\]\
B~MCI~ = 0.18 \[−0.06, 0.41\] *P* = .048B~AD~ = 0.43 \[0.03, 0.83\]\
B~MCI~ = 0.17 \[−0.14, 0.47\] *P* = .103B~AD~ = −0.009 \[−0.149, 0.132\]\
B~MCI~ = −0.005 \[−0.138, 0.128\] *P* = .99B~AD~ = −0.072 \[−0.283, 0.140\]\
B~MCI~ = −0.072 \[−0.243, 0.103\] *P* = .66WMH volumeB = 3.3E-5 \[−0.002, 0.002\] *P* = .30B = 0.002 \[−0.025, 0.030\] *P* = .83B = 0.0004 \[−0.0006, 0.001\] *P* = .21B = −0.002 \[−0.014, 0.009\] *P* = .30WMH volume \* Clinical diagnosis**B~AD~ = 0.001 \[−0.003, 0.006\]**\
**B~MCI~ = −0.004 \[−0.008, −0.0004\] *P* = .044**B~AD~ = −0.011 \[−0.068, 0.045\]\
B~MCI~ = −0.003 \[−0.038, 0.033\] *P* = .93B~AD~ = 0.002 \[−0.0007, 0.005\]\
B~MCI~ = −0.0008 \[−0.003, 0.001\] *P* = .14B~AD~ = 0.012 \[−0.013, 0.038\]\
B~MCI~ = 0.010 \[−0.009, 0.030\] *P* = .43Amyloid SUVR**B = −0.20 \[−0.43, 0.04\] *P* \< .001B = −0.18 \[−0.47, 0.10\] *P* \< .001**B = −0.026 \[−0.142, 0.090\] *P* = .34B = −0.043 \[−0.182, 0.095\] *P* = .93Amyloid SUVR \* Clinical diagnosis**B~AD~ = −0.61 \[−0.94, −0.28\]**\
**B~MCI~ = −0.23 \[−0.50, 0.05\] *P* = .001B~AD~ = −0.67 \[−1.09, −0.25\]**\
**B~MCI~ = −0.21 \[−0.57, 0.14\] *P* = .007**B~AD~ = −0.029 \[−0.193, 0.135\]\
B~MCI~ = −0.003 \[−0.161, 0.154\] *P* = .93B~AD~ = 0.042 \[−0.199, 0.283\]\
B~MCI~ = 0.074 \[−0.132, 0.282\] *P* = .77WMH volume \* Amyloid SUVRB = −0.003 \[−0.034, 0.028\]\
F(1,343) = 0.005, *P* = .95B = 0.003 \[−0.010, 0.017\] *P* = .37WMH volume \* Amyloid SUVR \* Clinical diagnosisB~AD~ = 0.012 \[−0.04, 0.07\]\
B~MCI~ = −0.002 \[−0.04, 0.04\] *P* = .88B~AD~ = −0.011 \[−0.039, 0.016\]\
B~MCI~ = −0.013 \[−0.036, 0.010\] *P* = .44Age**B = −0.012 \[−0.021, −0.003\] *P* = .013B = −0.012 \[−0.021, −0.003\] *P* = .013**B = −0.0005 \[−0.004, 0.003\] *P* = .81B = −0.0004 \[−0.004, 0.004\] *P* = .84SexB~M~ = −0.014 \[−0.056, 0.029\] *P* = .53B~M~ = −0.014 \[−0.056, 0.029\] *P* = .53B~M~ = −0.011 \[−0.030, 0.009\] *P* = .27B~M~ = −0.011 \[−0.030, 0.009\] *P* = .29APOE4**B~E4~ = 0.040 \[0.0001, 0.079\] *P* = .049**B~E4~ = 0.039 \[−0.0001, 0.079\] *P* = .051B~E4~ = 0.007 \[−0.012, 0.026\] *P* = .50B~E4~ = 0.006 \[−0.014, 0.025\] *P* = .55EducationB = 0.0006 \[−0.006, 0.007\] *P* = .85B = 0.0005 \[−0.006, 0.007\] *P* = .87B = 0.002 \[−0.0008, 0.005\] *P* = .15B = 0.002 \[−0.0008, 0.005\] *P* = .15Intracranial total volumeB = 5.3E-8 \[−8.0E-8, 1.9E-7\] *P* = .43B = 5.6E-8 \[−7.7E-8, 1.9E-7\] *P* = .41B = 3.5E−8 \[−2.4E-8, 9.4E-8\] *P* = .25B = 4.1E-8 \[−2.0E-8, 1.0E-7\] *P* = .19[^5]

Moreover, independent, pairwise growth curve models, which include time interactions ([Fig. 2](#fig2){ref-type="fig"}), showed that baseline AV45 SUVR was not associated with rate of change in WMH, but higher baseline WMH volume was associated with faster AV45 SUVR rate ([Supplementary Table 1](#appsec1){ref-type="sec"}). There was no significant association between baseline AV45 SUVR and cortical thinning rate ([Supplementary Table 2](#appsec1){ref-type="sec"}). There was a significant interaction between clinical diagnosis and baseline WMH volume on cortical thinning rate such that there was more cortical thinning with higher WMH volume in MCI and AD compared to NC ([Supplementary Table 2](#appsec1){ref-type="sec"}). In a full growth curve model, cortical thinning rate was not significantly associated with baseline WMH or baseline AV45 SUVR ([Table 3](#tbl3){ref-type="table"}). There were no significant interactions between AV45 SUVR and WMH volume on cortical thickness in the full linear mixed-effects model or on cortical thinning rate in the full growth curve model.

4. Discussion {#sec4}
=============

Profiles of multiple, abnormal biomarkers provide more insight into variations in the AD pathophysiological process compared with single biomarkers or clinical diagnosis, especially in the context of concurrent small vessel CVD, which we operationally define as WMH burden. This multimodal neuroimaging study indicates that increased amyloid pathology and WMH volume are related to lower cortical thickness and, importantly, suggests that WMHs are associated with neurodegeneration over time in key AD-associated regions, even in the absence of substantial amyloid burden. Similar to our findings, some studies suggest an additive effect of amyloid and CVD on neurodegeneration [@bib12], [@bib29], [@bib30], but others have suggested that CVD might act synergistically with AD pathology [@bib31], [@bib32], [@bib33], [@bib34].

There was an expected overlap of small vessel CVD and AD pathophysiology in that there was an increase in amyloid burden and WMH volume, as well as a decrease in cortical thickness across clinical diagnostic groups. While the finding was not significant, there was an unexpected slowing of cortical thinning rate in clinically defined AD compared with NC and MCI. Using biomarker classifications rather than clinical diagnostic groups, the focus of our analysis was shifted toward AD-associated and small vessel CVD--associated pathophysiology over clinical symptomatology. While we did not use a particularly sophisticated method to estimate abnormal amyloid or WMH burden thresholds, our thresholds produced similar results to previous studies [@bib28]. Thirty percent of normal controls had abnormally high amyloid burden, consistent with approximately 20%--40% of elderly individuals demonstrating elevated levels of amyloid, despite being cognitively normal [@bib1]. In addition, we found that 15% of clinically diagnosed AD cases had normally low amyloid, similar to the frequency of AD cases without pathology at autopsy [@bib9]. It should be noted that inclusion criteria of ADNI included a score of less than 4 on the Hachinski scale for history of hypertension and stroke, effectively including subjects with a low-to-moderate vascular risk [@bib16]. Individuals with the highest WMH volume were normal controls, possibly reflecting that symptomatic individuals (e.g., MCI, AD) with high degrees of CVD were excluded because of concerns of "mixed" pathology. Consequently, the WMH volumes in ADNI (0.08--1.18 cm^3^) are smaller than those observed in other studies (2.5--20.2 cm^3^) [@bib35]. These issues may have introduced bias into our analyses, potentially inflating type II statistical error rates (i.e., toward the null hypothesis). Using our abnormality threshold for WMH volume, approximately 55% of NC had high WMH burden at a mean age of approximately 75 years, similar to previous findings [@bib12].

Amyloid burden has been widely shown to be associated with neurodegeneration [@bib36], [@bib37], [@bib38], as our results demonstrated. Results are mixed concerning an association between AD pathology and WMH volume [@bib13], [@bib18], [@bib39], [@bib40]. Some studies attribute increased WMH in the context of clinical AD to Wallerian degeneration, or secondary damage due to primary AD pathology [@bib14], [@bib15]. Our results demonstrated no direct association between amyloid and WMH volume and that WMH was associated with future decrease in cortical thickness, suggesting that WMHs are not simply a reflection of Wallerian damage but rather promote neurodegeneration. Moreover, we found that baseline WMH volume was associated with amyloid accumulation rate but that baseline amyloid was not associated with WMH volume rate, also suggesting that WMHs are not simply a consequence of amyloidosis and that WMH may drive faster amyloid accumulation. Previous work in the ADNI cohort demonstrated an association between vascular risk factors and WMH volume after adjustment for amyloid burden [@bib16]. Our analyses here found a more negative association between WMH volume and cortical thickness and cortical thinning rate in a composite AD signature region, similar to associations between WMH volume and cortical volume found in the entorhinal cortex [@bib41] or hippocampus [@bib42]. We also found that cortical thinning over time was only significantly different from zero with high WMH burden, regardless of amyloid burden, suggesting that WMHs can indeed promote neurodegenerative changes. Similarly, animal studies demonstrate cortical atrophy in models of impaired cerebrovascular function [@bib43], [@bib44], and a previous study showed atrophy in AD-associated regions in the context of CVD but in the absence of AD pathology [@bib45]. Further work is necessary to fully understand the mechanism by which CVD leads to neurodegeneration.

Limitations of the present study include an unbalanced design in which models had different degrees of freedom based on available data, selection bias against overt CVD in the clinically diagnosed MCI and AD groups, and the restriction of biomarker measures to global or AD signature averages. It is possible that WMH volume reflects other pathologies than small vessel CVD, but previous work has shown an association between WMH volume and vascular risk factors in the ADNI cohort [@bib16]. Corrections for multiple comparisons to lower type I error were not performed despite running pairwise and full linear mixed-effects models and growth curve models due to the sampling bias against overt CVD, which would effectively raise the type II error. Strengths of the study include the large, multisite, multimodal and longitudinal nature of the ADNI study, which allowed us to observe associations even with the bias against overt CVD. A causal relationship between amyloid and WMH burden on cortical thickness cannot be determined definitively in observational studies, but the longitudinal design supports some degree of inference about the temporal ordering of these image-based biomarker changes (i.e., cortical thinning in those with high WMH burden). Future work includes extending this work to voxelwise analyses for more spatially specific conclusions in a population with a higher prevalence of CVD.

Overall, our findings indicate that amyloid burden and WMH volume additively contribute to overall cortical thickness and suggest that WMH volume contributes to the rate of cortical thinning in AD-associated regions, even in the absence of amyloid pathophysiology. In addition, in the presence of substantial amyloid burden, WMH could provide a second hit, increasing the cortical atrophy rate and contributing to clinical symptomatology [@bib29], [@bib32]. The respective importance of AD pathophysiology and CVD on neurodegeneration is of crucial significance for the development of effective preventive and therapeutic strategies.Research in Context1.Systematic review: The authors performed a literature search for amyloid deposition, white matter hyperintensity volume, and cortical thickness. While there were published articles that analyzed these metrics in the context of Alzheimer\'s disease, there were few studies that analyzed all three of these image-based biomarkers simultaneously in a large, longitudinal study.2.Interpretation: Our findings demonstrate the combined contribution of vascular disease and amyloid deposition to neurodegeneration during Alzheimer\'s disease progression.3.Future directions: This article identifies a relationship between vascular disease and Alzheimer\'s pathophysiology in a large, multisite, longitudinal study. This relationship will be further investigated in an ethnically and racially diverse cohort in which there is a higher risk of vascular disease.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0010}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: NOTE. Values are presented as mean parameter estimate \[95% CI\] and bolded if *P* \< .05. Rows represent all the variables included in a single linear mixed effects or growth curve model (column).

[^3]: \* Denotes significant difference from reference group (low amyloid, low WMH). \*\* Denotes significant difference from 0.

[^4]: NOTE. Values are presented as mean parameter estimate \[95% CI\] and bolded if *P* \< .05. Rows represent all the variables included in a single linear mixed effects or growth curve model (column).

[^5]: NOTE. Values are presented as mean parameter estimate \[95% CI\] and bolded if *P* \< .05. Rows represent all the variables included in a single linear mixed effects or growth curve model (column).
